necrostatin_1 [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.

Recent work by King et al. identified a novel role for the [[necroptosis]] inhibitor, necrostatin-1, in limiting neurovascular injury in tissue culture models of hemorrhagic injury. In the present study, they tested the hypothesis that necrostatin-1 reduces neurovascular injury after collagenase-induced [[intracerebral hemorrhage]] ICH in mice. Necrostatin-1 significantly reduced hematoma volume by 54% at 72 h after-ICH, as compared to either sham-injured mice or mice administered an inactive, structural analogue of necrostatin-1. Necrostatin-1 also limited cell death by 48%, reduced blood-brain barrier opening by 51%, attenuated edema development to sham levels, and improved neurobehavioral outcomes after ICH. These data suggest a potential clinical utility for necrostatin-1 and/or novel necroptosis inhibitors as an adjunct therapy to reduce neurological injury and improve patient outcomes after ICH
((King MD, Whitaker-Lea WA, Campbell JM, Alleyne CH Jr, Dhandapani KM.
Necrostatin-1 reduces neurovascular injury after intracerebral hemorrhage. Int J 
Cell Biol. 2014;2014:495817. doi: 10.1155/2014/495817. Epub 2014 Mar 6. PubMed
PMID: 24729786; PubMed Central PMCID: PMC3963111.
))